These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. IPO floodgates unlikely to open after Ark floatation. Louët S Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538 [No Abstract] [Full Text] [Related]
10. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective. Fiorino T J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065 [No Abstract] [Full Text] [Related]
11. Biotechs hold their own in shifting industry. Mitchell P Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238 [No Abstract] [Full Text] [Related]
13. The drug that could have been. Schultz S US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678 [No Abstract] [Full Text] [Related]
14. Keys to CRM success. How well are contract pharmaceutical companies doing in the CRM game? Kros JF; Molis J Mark Health Serv; 2004; 24(4):32-6. PubMed ID: 15612224 [No Abstract] [Full Text] [Related]
15. The closure of Sugen. Levitzki A Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548 [No Abstract] [Full Text] [Related]
16. Silent running: the race to the clinic. Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171 [No Abstract] [Full Text] [Related]